drugset
drugset / Trial / NCT04967625

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

NCT04967625 ↗

Phase 2 Unknown 23 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the efficacy and safety. 23 patients are expected to be enrolled in this study.

Timeline

Start
2021-07-26
Primary completion
2022-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

small cell lung carcinoma